RiskMetrics and Glass Lewis Support Nabi Biopharmaceuticals (NABI)' Proposed NicVAX Option and License Agreement  
2/18/2010 11:45:58 AM

ROCKVILLE, Md., Feb. 18, 2010 (GLOBE NEWSWIRE) -- Nabi Biopharmaceuticals (Nasdaq:NABI - News) (the "Company") announced today that RiskMetrics Group (ISS) and Glass Lewis & Co., two of the nation's leading independent proxy advisory firms, recommend that stockholders of the Company vote "FOR" the Company's exclusive option and license agreement for NicVAX®, (Nicotine Conjugate Vaccine) with GlaxoSmithKline Biologicals S.A., dated as of November 13, 2009, and the transactions contemplated thereby. ISS and Glass Lewis provide voting advice to hundreds of institutional investors, mutual and pension funds and other fiduciaries.